 |
|
Incidence of Hospitalized Rhabdomyolysis in Patients Treated With Lipid-Lowering Drugs
David J. Graham, MD, MPH;
Judy A. Staffa, PhD;
Deborah Shatin, PhD;
Susan E. Andrade, ScD;
Stephanie D. Schech, MPH;
Lois La Grenade, MD, MPH;
Jerry H. Gurwitz, MD;
K. Arnold Chan, MD, ScD;
Michael J. Goodman, PhD;
Richard Platt, MD, MSc
JAMA. 2004;292:(doi:10.1001/jama.292.21.2585).
Context Lipid-lowering agents are widely prescribed in the United States. Reliable estimates of rhabdomyolysis risk with various lipid-lowering agents are not available.
Objective To estimate the incidence of rhabdomyolysis in patients treated with different statins and fibrates, alone and in combination, in the ambulatory setting.
Design, Setting, and Patients Drug-specific inception cohorts of statin and fibrate users were established using claims data from 11 managed care health plans across the United States. Patients with at least 180 days of prior health plan enrollment were entered into the cohorts between January 1, 1998, and June 30, 2001. Person-time was classified as monotherapy or combined statin-fibrate therapy.
Main Outcome Measure Incidence rates of rhabdomyolysis per 10 000 person-years of treatment, number needed to treat, and relative risk of rhabdomyolysis.
Results In 252 460 patients treated with lipid-lowering agents, 24 cases of hospitalized rhabdomyolysis occurred during treatment. Average incidence per 10 000 person-years for monotherapy with atorvastatin, pravastatin, or simvastatin was 0.44 (95% confidence interval [CI], 0.20-0.84); for cerivastatin, 5.34 (95% CI, 1.46-13.68); and for fibrate, 2.82 (95% CI, 0.58-8.24). By comparison, the incidence during unexposed person-time was 0 (95% CI, 0-0.48; P = .056). The incidence increased to 5.98 (95% CI, 0.72-216.0) for combined therapy of atorvastatin, pravastatin, or simvastatin with a fibrate, and to 1035 (95% CI, 389-2117) for combined cerivastatin-fibrate use. Per year of therapy, the number needed to treat to observe 1 case of rhabdomyolysis was 22 727 for statin monotherapy, 484 for older patients with diabetes mellitus who were treated with both a statin and fibrate, and ranged from 9.7 to 12.7 for patients who were treated with cerivastatin plus fibrate.
Conclusions Rhabdomyolysis risk was similar and low for monotherapy with atorvastatin, pravastatin, and simvastatin; combined statin-fibrate use increased risk, especially in older patients with diabetes mellitus. Cerivastatin combined with fibrate conferred a risk of approximately 1 in 10 treated patients per year.
Author Affiliations: Office of Drug Safety, Center for Drug Evaluation and Research, Food and Drug Administration, Rockville, Md (Drs Graham, Staffa, and La Grenade); Center for Health Care Policy and Evaluation, Eden Prairie, Minn (Dr Shatin and Ms Schech); Meyers Primary Care Institute, Fallon Foundation and the University of Massachusetts Medical School, Worcester (Drs Andrade and Gurwitz); Channing Laboratory, Brigham and Women’s Hospital and Harvard Medical School (Drs Chan and Platt), Department of Ambulatory Care and Prevention, Harvard Pilgrim Health Care and Harvard Medical School (Dr Platt), and Department of Epidemiology, Harvard School of Public Health (Dr Chan), Boston, Mass; and HealthPartners Research Foundation, Minneapolis, Minn (Dr Goodman).
RELATED LETTERS
Rhabdomyolysis and Lipid-Lowering Drugs
Alexander Tenenbaum, Enrique Z. Fisman, and Michael Motro
JAMA. 2005;293(12):1448.
EXTRACT
| FULL TEXT
Rhabdomyolysis and Lipid-Lowering Drugs—Reply
David J. Graham, Judy A. Staffa, Lois La Grenade, Deborah Shatin, Stephanie D. Schech, Susan E. Andrade, Jerry H. Gurwitz, Michael J. Goodman, K. Arnold Chan, and Richard Platt
JAMA. 2005;293(12):1448-1449.
EXTRACT
| FULL TEXT
RELATED ARTICLES
Potential for Conflict of Interest in the Evaluation of Suspected Adverse Drug Reactions: Use of Cerivastatin and Risk of Rhabdomyolysis
Bruce M. Psaty, Curt D. Furberg, Wayne A. Ray, and Noel S. Weiss
JAMA. 2004;292(21):2622-2631.
ABSTRACT
| FULL TEXT
Potential for Conflict of Interest in the Evaluation of Suspected Adverse Drug Reactions: A Counterpoint
Brian L. Strom
JAMA. 2004;292(21):2643-2646.
EXTRACT
| FULL TEXT
Postmarketing Surveillance—Lack of Vigilance, Lack of Trust
Phil B. Fontanarosa, Drummond Rennie, and Catherine D. DeAngelis
JAMA. 2004;292(21):2647-2650.
EXTRACT
| FULL TEXT
Bayer’s Response to "Potential for Conflict of Interest in the Evaluation of Suspected Adverse Drug Reactions: Use of Cerivastatin and Risk of Rhabdomyolysis"
Joseph D. Piorkowski, Jr
JAMA. 2004;292(21):2655-2657.
EXTRACT
| FULL TEXT
Authors’ Reply to Bayer’s Response to "Potential for Conflict of Interest in the Evaluation of Suspected Adverse Drug Reactions: Use of Cerivastatin and Risk of Rhabdomyolysis"
Bruce M. Psaty, Curt D. Furberg, Wayne A. Ray, and Noel S. Weiss
JAMA. 2004;292(21):2658-2659.
EXTRACT
| FULL TEXT
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
|
Pharmacogenomics and Drug Toxicity
Nakamura
NEJM 2008;359:856-858.
FULL TEXT
Best Practices for Lowering the Risk of Cardiovascular Disease in Diabetes
Triplitt and Alvarez
Diabetes Spectr. 2008;21:177-189.
ABSTRACT
| FULL TEXT
Preventing further vascular events after a stroke or transient ischaemic attack: an update on medical management
Sudlow
PN 2008;8:141-157.
ABSTRACT
| FULL TEXT
Fabp3 as a Biomarker of Skeletal Muscle Toxicity in the Rat: Comparison with Conventional Biomarkers
Pritt et al.
Toxicol Sci 2008;103:382-396.
ABSTRACT
| FULL TEXT
Can cheap generic statins achieve national cholesterol lowering targets?
Petty and Lloyd
J Health Serv Res Policy 2008;13:99-102.
ABSTRACT
| FULL TEXT
Are patients with familial hypercholesterolaemia well managed in lipid clinics? An audit of eleven clinics from the Department of Health Familial Hypercholesterolaemia Cascade Testing project
Hadfield et al.
Ann Clin Biochem 2008;45:199-205.
ABSTRACT
| FULL TEXT
The efficacy and safety of intensive statin therapy: a meta-analysis of randomized trials
Josan et al.
CMAJ 2008;178:576-584.
ABSTRACT
| FULL TEXT
Rosuvastatin: Characterization of Induced Myopathy in the Rat
Westwood et al.
Toxicol Pathol 2008;36:345-352.
ABSTRACT
| FULL TEXT
Using population-based routine data for evidence-based health policy decisions: lessons from three examples of setting and evaluating national health policy in Australia, the UK and the USA
Morrato et al.
J Public Health (Oxf) 2007;29:463-471.
ABSTRACT
| FULL TEXT
Severe Rhabdomyolysis and Acute Renal Failure Secondary to Concomitant Use of Simvastatin, Amiodarone, and Atazanavir
Schmidt et al.
J Am Board Fam Med 2007;20:411-416.
ABSTRACT
| FULL TEXT
Atorvastatin-induced early-onset rhabdomyolysis in a patient with nephrotic syndrome
Jose et al.
Am J Health Syst Pharm 2007;64:726-729.
ABSTRACT
| FULL TEXT
The Use of Statins in Pediatrics: Knowledge Base, Limitations, and Future Directions
Belay et al.
Pediatrics 2007;119:370-380.
ABSTRACT
| FULL TEXT
Peroxisome Proliferator Activated Receptors as Transcriptional Nodal Points and Therapeutic Targets
Brown and Plutzky
Circulation 2007;115:518-533.
ABSTRACT
| FULL TEXT
Risks Associated With Statin Therapy: A Systematic Overview of Randomized Clinical Trials
Kashani et al.
Circulation 2006;114:2788-2797.
ABSTRACT
| FULL TEXT
The Triglyceride-Lowering Effects of a Modest Dose of Docosahexaenoic Acid Alone Versus in Combination with Low Dose Eicosapentaenoic Acid in Patients with Coronary Artery Disease and Elevated Triglycerides
Schwellenbach et al.
J. Am. Coll. Nutr. 2006;25:480-485.
ABSTRACT
| FULL TEXT
The Argument Against the Appropriateness of Over-the-Counter Statins
Barter and Rye
Circulation 2006;114:1315-1320.
FULL TEXT
Optimal Medical Management of Peripheral Arterial Disease
Rice and Lumsden
VASC ENDOVASCULAR SURG 2006;40:312-327.
ABSTRACT
Statin-Induced Myopathy: The Two Faces of Janus
Arora et al.
J CARDIOVASC PHARMACOL THER 2006;11:105-112.
ABSTRACT
Clinical Trials in the Wake of Vioxx: Requiring Statistically Extreme Evidence of Benefit to Ensure the Safety of New Drugs
Roth-Cline
Circulation 2006;113:2253-2259.
FULL TEXT
Management of Dyslipidemia in Special Populations
Tovar and Schering
Journal of Pharmacy Practice 2006;19:63-78.
ABSTRACT
Aspirin, statins, or both drugs for the primary prevention of coronary heart disease events in men: a cost-utility analysis.
Pignone et al.
ANN INTERN MED 2006;144:326-336.
ABSTRACT
| FULL TEXT
REVIEW: Efficacy and Mechanisms of Action of Statins in the Treatment of Diabetic Dyslipidemia
Ginsberg
J. Clin. Endocrinol. Metab. 2006;91:383-392.
ABSTRACT
| FULL TEXT
Drug induced myopathies
Mastaglia
PN 2006;6:4-13.
FULL TEXT
Medication-Attributed Adverse Effects in Placebo Groups: Implications for Assessment of Adverse Effects
Rief et al.
Arch Intern Med 2006;166:155-160.
ABSTRACT
| FULL TEXT
Reform of Drug Regulation -- Beyond an Independent Drug-Safety Board
Ray and Stein
NEJM 2006;354:194-201.
FULL TEXT
Outcomes in 45 Patients With Statin-Associated Myopathy
Hansen et al.
Arch Intern Med 2005;165:2671-2676.
ABSTRACT
| FULL TEXT
Lipids and CVD management: towards a global consensus
Ballantyne et al.
Eur Heart J 2005;26:2224-2231.
ABSTRACT
| FULL TEXT
2nd International Symposium on Triglycerides and HDL: Lipid abnormalities and their treatment
Diabetes Care 2005;28:2795-2802.
FULL TEXT
Lipids for Psychiatrists - an overview
Young
J Psychopharmacol 2005;19:66-75.
ABSTRACT
Diagnosis and Management of the Metabolic Syndrome: An American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement
Grundy et al.
Circulation 2005;112:2735-2752.
FULL TEXT
Evolving Concepts of Dyslipidemia, Atherosclerosis, and Cardiovascular Disease: The Louis F. Bishop Lecture
Gotto
J Am Coll Cardiol 2005;46:1219-1224.
FULL TEXT
The Year in Epidemiology, Health Services, and Outcomes Research
Krumholz
J Am Coll Cardiol 2005;46:1362-1370.
FULL TEXT
Differential Association Between Statin Exposure and Elevated Levels of Creatine Kinase
Chan et al.
The Annals of Pharmacotherapy 2005;39:1611-1615.
ABSTRACT
| FULL TEXT
Underappreciated Statin-Induced Myopathic Weakness Causes Disability
Dobkin
Neurorehabil Neural Repair 2005;19:259-263.
ABSTRACT
The Challenge of Achieving National Cholesterol Goals in Patients With Diabetes
Kennedy et al.
Diabetes Care 2005;28:1029-1034.
ABSTRACT
| FULL TEXT
Rhabdomyolysis and Lipid-Lowering Drugs
Tenenbaum et al.
JAMA 2005;293:1448-1448.
FULL TEXT
What's the Risk for Rhabdomyolysis from Lipid-Lowering Drugs?
Journal Watch Cardiology 2005;2005:3-3.
FULL TEXT
Statins and Rhabdomyolysis -- Clinical Data, Health Policy, and Politics
JWatch General 2005;2005:2-2.
FULL TEXT
Endocrinology & Metabolism News, January 2005
J. Clin. Endocrinol. Metab. 2005;90:16a-16a.
FULL TEXT
Postmarketing Surveillance--Lack of Vigilance, Lack of Trust
Fontanarosa et al.
JAMA 2004;292:2647-2650.
FULL TEXT
|
